Category Archives: Non classé

Five years of scientific progress, fruitful collaborations, and collective commitment in the fight against emerging and re-emerging respiratory viruses. We recently celebrated, in a warm and friendly atmosphere, the 5th anniversary of the International Research Laboratory #RESPIVIR (France–Canada), as well as its renewal for an additional five years to continue and accelerate our research efforts against infectious diseases. Many thanks to Bruno Lina and Laurent Schaeffer for bringing th...

#IMMUNOVIR aims to structure and develop our R&D partnership with the internationally renowned research center A*STAR Infectious Diseases Labs - A*STAR IDL. This program is structured around three complementary areas of research in the field of respiratory viral infections: (i) the study of immune responses to infections, (ii) the development of innovative diagnostic technologies, and (iii) new anti-infective immunotherapy strategies. Already supported by the #PHCMERLION program between U...

We are proud to announce that the STANDBYME project, led by Andrés Pizzorno, has been selected for the 2025 ANR Jeunes chercheuses – Jeunes chercheurs (JCJC) grant. Congratulations to Andrés and the entire RESPIVIR team for this outstanding achievement! STANDBYME aims to characterize the functional interactions between virus-infected cells and their surrounding “bystander” cells, which shape the pathophysiology and antiviral responses of the human upper respiratory tract. The project...

We are proud to announce the grant of our United States patent 12,285,433 B2, which protects the use of diltiazem as an activator of Interferon-λ (IFN-λ) expression for the prevention and/or treatment of microbial infections in human respiratory epithelia. Our research has shown that diltiazem, a calcium channel blocker currently used to treat angina, induces a broad-spectrum antiviral state in human respiratory epithelia without triggering the inflammation commonly associated with type I a...

We are proud to announce the grant of our European patent EP 4 090 334 B1 which protects the combination of diltiazem and baloxavir marboxil for use in the prevention and/or treatment of influenza virus infections, and representing a significant milestone in our commitment to innovative antiviral strategies.In a context where influenza infections continue to pose serious public health threats —due to the emergence of variants reducing vaccine efficacy and compromising current antiviral tre...

Virnext congratulates AIS Biotech on successfully raising €1.5 million to advance the development of its innovative therapies for infectious diseases. This funding will support the preclinical development of GlycoFlu, their novel drug candidate for influenza, and strengthen their technological platform for sugar-based bioproduction, designed to target additional pathogens. This milestone reflects the confidence of AIS Biotech’s partners and investors in the company’s strategy and technolog...

RESPIVIR and its technological research platform Virnext are very proud to be partners in two public–private R&D consortia focused on respiratory viral infectious diseases. #SHIELD Project The #SHIELD project aims to revolutionize the control of airborne infectious risk in hospitals by developing innovative, deployable, and more sustainable controlled environment solutions. It is part of a broader effort to support healthcare infrastructure by: improving responsiveness in the eve...

We will be taking part in the 4th edition of Tech365 Meetings, the 100% online annual event dedicated to innovation and technology transfer, on 1 July 2025! Tech365 provides virnext with the opportunity to discover breakthrough technologies emerging from public research and deeptech, while exploring potential avenues for technological synergies and translational research partnerships. See you on 1 July, for one-to-one virtual meetings....

This study aimed to characterize the infection kinetics and long-term epithelial innate responses to IAV H1N1, RSV-A, and SARS-CoV-2 in a human nasal epithelial model (MucilAir™) cultured at air-liquid interface. Replication, tissue integrity, host gene expression, and epithelium morphology were assessed up to 28 days post-infection (dpi). Our results show that IAV, RSV, and SARS-CoV-2 trigger distinct, long-lasting epithelial responses in the absence of immune cells, highlighting virus-specif...

Virnext congratulates VirexpR on the inauguration of its modular biosafety laboratory, IMePOD, in the Auvergne-Rhône-Alpes region. This new facility enhances their ability to advance research on airborne infectious contamination and indoor air quality across key sectors including transportation, healthcare, pharmaceutical, agri-food and animal husbandry. The inauguration, presided over by Catherine Staron, Vice-President of the Auvergne-Rhône-Alpes Region, brought together academic and indu...